Results

Total Results: 635 records

Showing results for "topical treatment".

141. Final Research Plan: Prediabetes and Type 2 Diabetes: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/screening-for-prediabetes-and-type-2-diabetes
     November 15, 2018 - improve health outcomes compared with no intervention, usual care, or interventions with different treatment … improve health outcomes compared with no intervention, usual care, or interventions with different treatment … threshold) KQs 4, 5: No intervention, placebo, usual care (can include minimal intervention), different treatment … , harms from false-positive results, burden, inconvenience, depression, and unnecessary testing and treatment … KQ 6: Serious side effects from treatment, including mortality, myocardial infarction, stroke, cancer

142. Procedure Manual Section 7. Formulation of Task Force Recommendations | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/procedure-manual/procedure-manual-section-7-formulation-task-force-recommendations
     in context (clinical context, societal values for specific outcomes, and context of intervention and treatment … the population of interest, recommendation, risk assessment, screening or intervention of interest, treatment

143. Final Research Plan: Hepatitis B Virus Infection in Adolescents and Adults: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/hepatitis-b-virus-infection-screening
     March 14, 2019 - Interventions KQs 1–3: Screening, including alternative screening strategies (KQ 3) KQs 4–7: Antiviral treatments … Therapies will be classified as: Preferred: Pegylated interferon (adults), nonpegylated interferon … tenofovir alafenamide Nonpreferred: Lamivudine, adefovir, and telbivudine KQs 4–7: Antiviral treatments … not approved by the FDA; combination therapy Comparators KQs 1, 2: No screening KQ 3: … nonpreferred antiviral therapies KQ 7: Effects on intermediate outcome (HBV DNA level, HBeAg status

144. Final Research Plan: Hepatitis C Virus Infection in Adolescents and Adults: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/hepatitis-c-screening
     December 21, 2017 - What are the harms of currently recommended antiviral treatments? * 9.    … 7, and 8 include those defined by age, race/ethnicity, sex, drug use, receipt of maximally assisted therapy … What is the effect of antiviral treatments on behavioral outcomes? … clinical outcomes (KQ 9) Populations Persons with HCV infection being treated with antiviral therapy … behavioral health care; subpopulations of interest include drug use, persons using medication-assisted therapies

145. Screening for Syphilis Infection in Pregnant Women: Evidence for the Reaffirmation Recommendation Statement (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/gWJU-ZynehGyLBVYtDmMow
     May 01, 2009 - , 3% received delayed treatment, 3% declined treatment, and 2% were lost to follow-up. … syphilis before or during pregnancy, including 22.6% who did not have an adequate serologic response to therapy … Compared treatments or supplements used by at least 0.5% of pregnant women during critical periods who … failed, 5 to women who declined treatment, and 7 to women who received late treatments. … Previous reports of 1–5 anaphylactic reactions per 100 000 treatments.

146. Summary of USPSTF Final Recommendation: Screening for Osteoporosis to Prevent Fractures (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/E24AtkYp7cR8bp864K4CGS
     January 01, 2025 - www.niams.nih.gov/health-topics/osteoporosis https://www.niams.nih.gov/health-topics/osteoporosis/diagnosis-treatment-and-steps-to-take

147. Final Research Plan: Latent Tuberculosis Infection in Adults: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/latent-tuberculosis-infection-screening
     June 17, 2021 - or who had received no more than a few weeks of treatment. … observed therapy for 6 or 9 months, RIF daily for 4 months, or INH plus RPT weekly by directly observed … therapy for 3 months) compared with placebo, no treatment, delayed treatment, or another eligible treatment … KQs 3, 5: Studies comparing other treatments or combinations (i.e., regimens that are not recommended … KQ 4: False-positive results leading to unnecessary testing or treatment, labeling, stigma, anxiety,

148. Archived: Final Research Plan: Breast Cancer: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan97/breast-cancer-screening-january-2016
     July 17, 2014 - carcinoma in situ, atypical ductal or lobular hyperplasia); or previous large doses of chest radiation therapy … carcinoma in situ, atypical ductal or lobular hyperplasia); or previous large doses of chest radiation therapy … density, parity, race/ethnicity, age at first birth, menopausal status, current use of menopausal hormone therapy … situ, atypical ductal or lobular hyperplasia); or women with previous large doses of chest radiation therapy … adverse effects of treatment, quality of life measures, other measures of impairment).

149. Archived: Final Research Plan: Chlamydia and Gonorrhea: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan21/chlamydia-and-gonorrhea-screening-september-2014
     June 15, 2013 - adverse events, they may be diagnosed with a gonococcal or chlamydia infection, and they may go through treatment … The treatment could lead to reduced complications of the gonococcal or chlamydial infection, and it may … The treatment could lead to reduced complications of the gonococcal or chlamydial infection and to reduced … The treatment could also lead to reduced tramsmission of the infection to the newborn, and it may lead … Treatment harms will be discussed in the background section of the systematic review.

150. Evidence Gaps Research Taxonomy Table: Screening for Osteoporosis to Prevent Fractures (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/kHT3WGUaG2wTz2pF_ke7bn
     fractures) Fracture-related morbidity (e.g., disability) KQ3: Overdiagnosis resulting in unnecessary treatment … fractures) Fracture-related morbidity (e.g., disability) KQ3: Overdiagnosis resulting in unnecessary treatment … population for model validation Harms: Overdiagnosis resulting in unnecessary treatment Radiation … population Bisphosphonates with FDA-approved indications for the treatment of osteoporosis (i.e … gastrointestinal cancer, serious gastrointestinal events, rebound fractures after discontinuing denosumab treatment

151. Recommendation: Food Insecurity: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/recommendation/food-insecurity-screening
     March 11, 2025 - more. 17-19 It is derived from, and validated against, the USDA Household Food Security Survey. 19 Treatment … , primary interest in other outcomes or comparative effectiveness). 3 , 33 Harms of Screening and Treatment … Primary care–based and primary care–referrable interventions generally offer only limited “treatment” … Benefits of early detection and intervention and treatment Inadequate direct evidence about screening … Harms of early detection and intervention and treatment Inadequate evidence on the harms of screening

152. Screening for Obstructive Sleep Apnea in Adults (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/VwvmgA5bLZZJhK6YSqRonU
     November 01, 2022 - • Treatment with continuous positive airway pressure or mandibular advancement devices can improve … apnea-hypopnea index, Epworth Sleepiness Scale score, and blood pressure) in populations referred for treatment

153. 11th Annual Report to Congress on High-Priority Evidence Gaps for Clinical Preventive Services (pdf file)
     www.uspreventiveservicestaskforce.org/uspstf/sites/default/files/inline-files/2021-uspstf-annual-report-to-congress.pdf
     January 01, 2021 - • Assess the effects of lifestyle interventions and medical treatments for screen-detected prediabetes … Potential harms may include inaccurate test results, harms from invasive followup tests, harms from treatment … • Assess the effects of lifestyle interventions and medical treatments for screen-detected prediabetes … Final Research Plan Menopausal Hormone Therapy to Prevent Chronic Conditions Oral Health in Youth … Deficiency Draft Research Plan Folic Acid to Prevent Neural Tube Defects Menopausal Hormone Therapy

154. Final Research Plan: Nonpregnant Adolescents and Adults: Human Immunodeficiency Virus (HIV) Infection: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan-nonpregnant-adolescents-and-adults/human-immunodeficiency-virus-hiv-infection-screening
     June 15, 2017 - . †  Harms of treatment include adverse effects associated with antiretroviral therapy, including cardiometabolic … studies KQ 5: Randomized, controlled trials and controlled observational studies; will consider treatment … diagnostic staging step, and clarify that the evidence review will focus on the benefits and harms of treatment … with antiretroviral therapy. … therapy regimens."

155. Final Research Plan: Pregnant Women: Human Immunodeficiency Virus (HIV) Infection: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan-pregnant-women/human-immunodeficiency-virus-hiv-infection-screening
     June 15, 2017 - . †  Harms of treatment include adverse maternal and infant outcomes associated with use of antiretroviral … therapy. … treatment interruption Comparisons KQs 1, 3: HIV screening vs. no screening KQ 2: Repeat … the USPSTF revised the analytic framework to differentiate the harms of screening from the harms of treatment … diagnostic staging step, and clarify that the evidence review will focus on the benefits and harms of treatment

156. Archived: Final Research Plan: Skin Cancer: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan104/skin-cancer-screening-july-2016
     July 17, 2014 - Finally, key question 6 addresses the harms that are associated with the treatment of skin cancer by … What are the harms of surgical treatment of skin cancer?

157. Archived: Final Research Plan: Osteoporosis to Prevent Fractures: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/osteoporosis-screening-june-2018
     November 05, 2015 - For adults with increased risk for osteoporotic fractures, treatment may reduce the likelihood of fractures … Treatment may result in harms (KQ 5). … What are the harms associated with treatment with pharmacotherapy? … Food and Drug Administration for the treatment or prevention of osteoporosis (including bisphosphonates … , estrogen agonists/antagonists, hormone therapy, calcitonin, parathyroid hormone, and RANKL inhibitors

158. Testimony for the House Energy and Commerce Health Subcommittee Hearing (pdf file)
     www.uspreventiveservicestaskforce.org/uspstf/sites/default/files/inline-files/tfcongresstestimony%20(3).pdf
     November 30, 2016 - and because many sub-specialists have specific ties to the industries that make screening tests or treatments … that I can give Ruth a complete understanding of potential side effects of these tests 3 and treatments … Those providers whose livelihoods are affected by the diagnosis and treatment of disease—as is the … specific ties (including as consultants or speakers) to the industries that make screening tests or treatments

159. Final Research Plan: Prostate Cancer: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/prostate-cancer-screening
     April 28, 2016 - varying the age at which to start/stop screening, the screening interval, the threshold for biopsy, and treatments … (androgen deprivation therapy via luteinizing hormone-releasing hormone agonists, antiandrogen therapy … , and/or orchiectomy) Ultrasonography (high-intensity focused ultrasonography) Radiation therapy … (external-beam radiation therapy, proton beam therapy, brachytherapy, combination therapies) Ablative … prostate hyperplasia) that are not generally associated with an increased risk for prostate cancer. 1 † Treatments

160. Screening for Asymptomatic Bacteriuria in Adults: Updated Evidence Report and Systematic Review for the USPSTF (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/8YfPLRoMwTeaDgxJdYnYbb
     September 24, 2019 - identified 5.0% of women who were screened with dip slide as positive for asymptomatic bacteriuria.33 Treatments … women reported that there were no adverse drug reactions among the 49 women treated with nitrofurantoin therapy … women treated with trimethoprim.28 Another reported that 2 of 32 women (6%) assigned to daily ofloxacin therapy … Therapy vs no therapy for bacteriuria in elderly ambulatory nonhospitalized women. … Urinary tract infections in pregnancy: old and new unresolved diagnostic and therapeutic problems.